Compare 3M Company (MMM) vs Moderna, Inc. (MRNA) Price & Performance

3M (MMM) surged 6.83% to $170.76 following strong Q2 2026 earnings that beat expectations, with the company raising full-year guidance. Technical indicators show a bullish trend with support at $158 and resistance at $161. Fundamentally, the company demonstrates robust profitability with 39.71% gross margins and 72.14% ROE, though revenue has declined from 2022 peaks. Recent news highlights operational improvements and growth in Safety & Industrial and Transport & Electronics segments.

The outlook is positive with earnings momentum and raised guidance, but risks include litigation liabilities and macroeconomic headwinds. Analyst consensus is mixed with 48% buy ratings but a $149.75 price target below current levels, suggesting limited near-term upside despite strong operational performance.

Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.

Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.